Objective: The aim of this research is to study the effect of time factors on the mortality of brittle hip fracture.
Methods: The data of 705 patients of hip fracture hospitalized at our department from 2010 to 2012 were reviewed. Among them, 499 cases undergoing surgical operation over the age of 50 were followed up, and 250 cases had valid follow-up records. The effects of the time from injury to operation, the time from injury to hospitalization and the time from hospitalization to operation on the mortality were analyzed.
Results: The average duration of follow-up was 21.37 ± 9.77 months. There were 198 cases which were followed up for over 12 months. Nine patients died within 3 months after the hip fracture surgery, and 13 patients died within 1 year. A total of 25 patients died during the follow-up. The survival rate of patients with the interval from injury to surgery longer than 5 days was lower than that of patients with the interval less than or equal to 5 days (p = 0.014). The survival rate of patients with the interval from injury to hospitalization longer than 2 days was lower than that of patients with the interval from injury to hospitalization less than or equal to 2 days (p = 0.003). There was no statistical significance in the survival rate between patients with the interval from hospitalization to surgery longer than 3 days and that of patients with the interval from hospitalization to surgery less than or equal to 3 days (p = 0.973).
Conclusion: The operational delay, especially the delay of time from injury to hospitalization, is an important factor affecting the early mortality of hip fracture. The delay of time from hospitalization to operation is mainly due to the consideration of the patients' situation and has no effect on early mortality.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025195 | PMC |
http://dx.doi.org/10.1186/1749-799X-9-37 | DOI Listing |
Paediatr Drugs
January 2025
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Background: This study aimed to provide a comprehensive review of adverse events (AEs) associated with factor Xa (FXa) inhibitors in pediatric patients.
Methods: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the European Union Clinical Trials Register for English-language records from the establishment of the database up to October 17, 2023.
Cardiol Ther
January 2025
Adult Medicine, Department of Clinical Medical Sciences, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.
Introduction: This prospective, single-arm pharmacodynamic study assessed the effect of colchicine (COLC) [Strides Pharma UK Ltd, Watford, Hertfordshire, England] 0.5 mg administered orally once daily for 14 days on platelet reactivity with respect to aspirin reaction units (ARUs) and P2Y reaction units (PRUs).
Methods: Twenty-two patients with stable coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) with daily maintenance aspirin and clopidogrel were recruited.
Jpn J Ophthalmol
January 2025
Department of Ophthalmology, Graduate of Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Purpose: To assess the efficacy and safety of PreserFlo MicroShunt (PMS) combined with mitomycin C in patients with medically treated primary open-angle glaucoma (POAG).
Study Design: A retrospective observational study.
Methods: The study examined 83 eyes from 83 patients with medically treated glaucoma surgery naive POAG.
Metab Brain Dis
January 2025
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N, Denmark.
Background & Aims: Hepatic encephalopathy (HE), one of the most serious prognostic factors for mortality in alcohol-related cirrhosis (ALD cirrhosis), is not recorded in Danish healthcare registries. However, treatment of HE with lactulose, the universal first-line treatment, can be identified through data on filled prescriptions. This study aimed to investigate if lactulose can be used as a surrogate marker of HE.
View Article and Find Full Text PDFRheumatol Int
January 2025
School of Medicine, The University of Western Australia, 35 Stirling Highway, Perth, WA, 6009, Australia.
This study aims to review the literature and estimate the global pooled prevalence of interstitial lung disease among patients with rheumatoid arthritis (RA-ILD). The influence of risk factors like geography, socioeconomic status, smoking and DMARD use will be explored. A systematic review was performed according to the PRISMA and JBI guidelines.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!